Blog
About

4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Silibinin inhibits the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2.

      Molecular carcinogenesis

      Urokinase-Type Plasminogen Activator, metabolism, Cell Adhesion, drug effects, Cell Movement, Cell Survival, Blotting, Western, Dose-Response Relationship, Drug, Humans, Lung Neoplasms, enzymology, pathology, Matrix Metalloproteinase 2, Milk Thistle, Neoplasm Invasiveness, Plasminogen Activators, Reverse Transcriptase Polymerase Chain Reaction, Silymarin, pharmacology, Time Factors, Tissue Inhibitor of Metalloproteinase-2, Tumor Cells, Cultured, Antineoplastic Agents

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Cancer metastasis, involving multiple processes and various cytophysiological changes, is a primary cause of cancer death and may complicate the clinical management, even lead to death. Silibinin is a flavonoid antioxidant and wildly used for its antihepatotoxic properties and recent studies have revealed pleiotropic anticancer and antiproliferative capabilities of silibinin. In this study, we first observed that silibinin exerted a dose- and time-dependent inhibitory effect on the invasion and motility, but hardly on the adhesion, of highly metastatic A549 cells in the absence of cytotoxicity. To look at the precise involvement of silibinin in cancer metastasis, A549 cells were treated with silibinin at various concentrations, up to 100 microM, for a defined period and then subjected to gelatin zymography, casein zymography and Western blot to investigate the impacts of silibinin on metalloproteinase-2 (MMP-2), urokinase plasminogen activator (u-PA), and tissue inhibitor of metalloproteinase-2 (TIMP-2), respectively. The results showed that a silibinin treatment may decrease the expressions of MMP-2 and u-PA in a concentration- and time-dependent manner and enhance the expression of TIMP-2. Further analysis with semi-quantitative RT-PCR showed that silibinin may regulate the expressions of MMP-2 and u-PA on the transcriptional level while on the translational or post-translational level for TIMP-2. Copyright 2004 Wiley-Liss, Inc.

          Related collections

          Author and article information

          Journal
          10.1002/mc.20018
          15224346

          Comments

          Comment on this article